48

DAFTAR PUSTAKA

1. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C;

Infectious Diseases Society of America. Update of practice guidelines for

the management of community-acquired pneumonia in immunocompetent

adults.Clin Infect Dis.2003;37:1405-1433.

2. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ.

Practice guidelines for the management of community-acquired

pneumonia in adults. Infectious Diseases Society of America. Clin Infect

Dis. 2000;31:347-382. Epub 2000 Sep 07.

3. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA,

et al. The burden of community-acquired pneumonia in seniors: results of

a population-based study. Clin Infect Dis. Dec 1 2004;39(11):1642-50.

4. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in

North American adults. Postgrad Med. Mar 2010;122(2):130-41

5. Amrita. Evaluasi penggunaan antibiotik empirik pada penderita

Community-Acquired Pneumonia (CAP) yang dirawat di RSUP dr.

Kariadi Semarang. Semarang: Universitas Diponegoro. 2010.

6. Brett J,Lam V, Baysari MT, Milder T, Killen L, Chau A, et al. Pneumonia

severity scores and prescribing antibiotics for community-acquired

49

pneumonia at an Australian hospital Journal of Pharmacy Practice and

Research, Vol. 43, No. 2, Jun 2013: 97-100.

7. Mocelin CA, Santos RP. Community-acquired Pneumonia at the Hospital

de Clinicas de Porto Alegre: evaluation of a care protocol. Braz J Infec

Dis.2013;17:511-5 - Vol. 17 Num.5 DOI: 10.1016/j.bjid.2012.11.013

8. Niederman MS, Mandell LA, Anzueto A, Bass, JB, Broughton WA,

Campbell GD, et al; American Thoracic Society. Guidelines for the

management of adults with community-acquired pneumonia: Diagnosis,

assessment of severity, antimicrobial therapy, and prevention. Am J Respir

Crit Care Med.2001;163:1730-1754.

9. Lim I, Shaw DR, Stanley DP, et al. A prospective hospital study of the

aetiology of community-acquired pneumonia. Med J Aust 1989; 151: 87-

91.

10. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical

northern Australia: a 10-year prospective study and review of the

literature. Clin Infect Dis 2000; 31: 981-986

11. Anstey NM, Currie BJ, Withnall KM. Community-

acquired Acinetobacter pneumonia in the Northern Territory of

Australia. Clin Infect Dis 1992; 14: 83-91.

12. File TM. Community-acquired pneumonia. Lancet 2003; 362:1991–2001.

13. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Summary

of Canadian Guideline for the Initial Management of Community-acquired

Pneumonia : An evidence-based update by the Canadian Infectious

50

Disease Society and the Canadian Thoracic Society. Can J Infect

Dis. 2000 Sep-Oct; 11(5): 237–248.

14. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean

NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A,

Whitney CG, Infectious Diseases Society of America, American Thoracic

Society Clin Infect Dis.2007 Mar 1; 44 Suppl 2():S27-72.

15. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town

GI, et al. Defining community acquired pneumonia severity on

presentation to hospital: an international derivation and validation study.

Thorax 2003; 58:377–382.

16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et

al. A prediction rule to identify low-risk patients with community-acquired

pneumonia.NEngl J Med 1997; 336:243–50.

17. Halm EA, Atlas SJ, Borowsky LH,Benzer TI, Metlay JP, Chang YC, and

Singer DE. Understanding physician adherence with a pneumonia practice

guideline: effects of patient, system, and physician factors. Arch Intern

Med 2000; 160:98–104.

18. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-

acquired pneumonia: a prospective study of patients not initially admitted

to the ICU. Chest 2005; 127:1260–70.

19. Goss CH, Rubenfeld GD, Park DR, Sherbin VL, Goodman MS, Root RK.

Cost and incidence of social comorbidities in low-risk patients with

51

community-acquired pneumonia admitted to a public hospital.Chest 2003;

124:2148–55.

20. Metlay JP, Fine MJ. Testing strategies in the initial management of

patients with community-acquired pneumonia. Ann Intern Med 2003;

138:109–18.

21. Suchyta MR, Dean NC, Narus S, Hadlock CJ. Effects of a practice

guideline for community-acquired pneumonia in an outpatient setting. Am

J Med 2001; 110:306–9.

22. Watkins RR, Lemonovich TL. Diagnosis and Management of Community-

Acquired Pneumonia in Adults. Am Fam

Physician. 2011 Jun 1;83(11):1299-1306.

23. Armitage K, Woodhead M; Lippincott Williams & Wilkins. New

guidelines for the management of adult community-acquired pneumonia.

Curr Opin Infect Dis 2007; 20:170–176.

24. Blot, S.I., Rodriguez, A., Solé-Violán, J., Blanquer, J., Almirall, J. and

Rello, J. Effects of delayed oxygenation assessment on time to antibiotic

delivery and mortality in patients with severe community-acquired

pneumonia. Crit Care Med 2007; 35: 2509–2514

25. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et

al. BTS guidelines for the management of community acquired pneumonia

in adults: update 2009. Thorax 2009;64:iii1-

iii55 doi:10.1136/thx.2009.121434

52

26. Roson B, Carratala J,Dorca J, Casanova A, Manresa F, and Gudiol F.

Etiology, Reasons for Hospitalization, Risk Classes, and Outcomes of

Community-Acquired Pneumonia in Patients Hospitalized on the Basis of

Conventional Admission Criteria. Clin Infect Dis 2001 Jul 15;33(2):158-

65

27. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive

rule for the management of community-acquired pneumonia. Eur Respir J

2006; 27:151–7.

28. Ochoa-Gonder O, Vila-Corcoles A, Diego C, et al. The burden of CAP in

the elderly: the Spanish Evan-65 study. BMC Public Health 2008; 8: 222–

222.

29. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three

validated prediction rules for prognosis in community-acquired

pneumonia. Am J Med 2005; 118:384–92

30. Surjanto E, Sutanto YS, Reviono, et al. Perbandingan Tiga Metode

Prediksi secara Retrospektif dalam Menilai Derajat Pneumonia Komunitas

pada Pasien Lanjut Usia di Rumah Sakit Dr. Moewardi Surakarta. J

Respir Indo. 2013; 33:34-9

31. Shah BA, Ahmed W, Dhobi GN, et al. Validity of Pneumonia Severity

Index and CURB-65 Severity Scoring Systems in Community Acquired

Pneumonia in an Indian Setting. The Indian Journal of Chest Diseases &

Allied Sciences 2010;Vol.52

53

Lampiran 1. Analisis univariat data responden

Usia

21 30.9 30.9 30.9

47 69.1 69.1 100.0

68 100.0 100.0

<= 60

> 60

Total

ValidFrequency Percent Valid Percent

CumulativePercent

Jenis kelamin

33 48.5 48.5 48.5

35 51.5 51.5 100.0

68 100.0 100.0

Laki-laki

Perempuan

Total

ValidFrequency Percent Valid Percent

CumulativePercent

Tempat rawat

62 91.2 91.2 91.2

6 8.8 8.8 100.0

68 100.0 100.0

non-ICU

ICU

Total

ValidFrequency Percent Valid Percent

CumulativePercent

Kelompok risiko PSI

1 1.5 1.5 1.5

4 5.9 5.9 7.4

9 13.2 13.2 20.6

31 45.6 45.6 66.2

23 33.8 33.8 100.0

68 100.0 100.0

I

II

III

IV

V

Total

ValidFrequency Percent Valid Percent

CumulativePercent

PSI

14 20.6 20.6 20.6

31 45.6 45.6 66.2

23 33.8 33.8 100.0

68 100.0 100.0

rendah

sedang

tinggi

Total

ValidFrequency Percent Valid Percent

CumulativePercent

54

Keganasan

Frequency Percent Valid Percent

Cumulative

Percent

Valid Ya 3 4.4 4.4 4.4

Tidak 65 95.6 95.6 100.0

Total 68 100.0 100.0

Total skor CURB

2 2.9 2.9 2.9

8 11.8 11.8 14.7

39 57.4 57.4 72.1

16 23.5 23.5 95.6

2 2.9 2.9 98.5

1 1.5 1.5 100.0

68 100.0 100.0

0

1

2

3

4

5

Total

ValidFrequency Percent Valid Percent

CumulativePercent

CURB

10 14.7 14.7 14.7

39 57.4 57.4 72.1

19 27.9 27.9 100.0

68 100.0 100.0

rendah

sedang

tinggi

Total

ValidFrequency Percent Valid Percent

CumulativePercent

55

penyakit liver

Frequency Percent Valid Percent

Cumulative

Percent

Valid Ya 3 4.4 4.4 4.4

Tidak 65 95.6 95.6 100.0

Total 68 100.0 100.0

CHF

Frequency Percent Valid Percent

Cumulative

Percent

Valid Ya 19 27.9 27.9 27.9

Tidak 49 72.1 72.1 100.0

Total 68 100.0 100.0

penyakit serebrovaskuler

Frequency Percent Valid Percent

Cumulative

Percent

Valid Ya 10 14.7 14.7 14.7

Tidak 58 85.3 85.3 100.0

Total 68 100.0 100.0

56

penyakit ginjal

Frequency Percent Valid Percent

Cumulative

Percent

Valid Ya 11 16.2 16.2 16.2

Tidak 57 83.8 83.8 100.0

Total 68 100.0 100.0

terapi empirik

Frequency Percent Valid Percent

Cumulative

Percent

Valid ceftriaxone 50 73.5 73.5 73.5

ciprofloxacin 3 4.4 4.4 77.9

levofloxacin 1 1.5 1.5 79.4

meropenem 2 2.9 2.9 82.4

cefotaxime 2 2.9 2.9 85.3

cefoperazone 1 1.5 1.5 86.8

ceftriaxone+ciprofloxacin 6 8.8 8.8 95.6

ceftriaxone+cefotaxime 1 1.5 1.5 97.1

ciprofloxacin+clindamycin 1 1.5 1.5 98.5

levofloxacin+meropenem 1 1.5 1.5 100.0

Total 68 100.0 100.0

57

Lampiran 2. Analisis bivariat data responden

Crosstab

9 8 4 21

4.3 9.6 7.1 21.0

64.3% 25.8% 17.4% 30.9%

13.2% 11.8% 5.9% 30.9%

5 23 19 47

9.7 21.4 15.9 47.0

35.7% 74.2% 82.6% 69.1%

7.4% 33.8% 27.9% 69.1%

14 31 23 68

14.0 31.0 23.0 68.0

100.0% 100.0% 100.0% 100.0%

20.6% 45.6% 33.8% 100.0%

Count

Expected Count

% within PSI

% of Total

Count

Expected Count

% within PSI

% of Total

Count

Expected Count

% within PSI

% of Total

<= 60

> 60

Usia

Total

rendah sedang tinggi

PSI

Total

Chi-Square Tests

9.654a 2 .008

9.163 2 .010

7.801 1 .005

68

Pearson Chi-Square

Likelihood Ratio

Linear-by-LinearAssociation

N of Valid Cases

Value dfAsymp. Sig.

(2-sided)

1 cells (16.7%) have expected count less than 5. Theminimum expected count is 4.32.

a.

58

Crosstab

8 12 1 21

3.1 12.0 5.9 21.0

80.0% 30.8% 5.3% 30.9%

11.8% 17.6% 1.5% 30.9%

2 27 18 47

6.9 27.0 13.1 47.0

20.0% 69.2% 94.7% 69.1%

2.9% 39.7% 26.5% 69.1%

10 39 19 68

10.0 39.0 19.0 68.0

100.0% 100.0% 100.0% 100.0%

14.7% 57.4% 27.9% 100.0%

Count

Expected Count

% within CURB

% of Total

Count

Expected Count

% within CURB

% of Total

Count

Expected Count

% within CURB

% of Total

<= 60

> 60

Usia

Total

rendah sedang tinggi

CURB

Total

Chi-Square Tests

17.145a 2 .000

18.081 2 .000

15.875 1 .000

68

Pearson Chi-Square

Likelihood Ratio

Linear-by-LinearAssociation

N of Valid Cases

Value dfAsymp. Sig.

(2-sided)

1 cells (16.7%) have expected count less than 5. Theminimum expected count is 3.09.

a.

59

Crosstab

7 13 13 33

6.8 15.0 11.2 33.0

50.0% 41.9% 56.5% 48.5%

10.3% 19.1% 19.1% 48.5%

7 18 10 35

7.2 16.0 11.8 35.0

50.0% 58.1% 43.5% 51.5%

10.3% 26.5% 14.7% 51.5%

14 31 23 68

14.0 31.0 23.0 68.0

100.0% 100.0% 100.0% 100.0%

20.6% 45.6% 33.8% 100.0%

Count

Expected Count

% within PSI

% of Total

Count

Expected Count

% within PSI

% of Total

Count

Expected Count

% within PSI

% of Total

Laki-laki

Perempuan

Jenis kelamin

Total

rendah sedang tinggi

PSI

Total

Chi-Square Tests

1.140a 2 .566

1.144 2 .565

.294 1 .588

68

Pearson Chi-Square

Likelihood Ratio

Linear-by-LinearAssociation

N of Valid Cases

Value dfAsymp. Sig.

(2-sided)

0 cells (.0%) have expected count less than 5. Theminimum expected count is 6.79.

a.

60

Crosstab

4 20 9 33

4.9 18.9 9.2 33.0

40.0% 51.3% 47.4% 48.5%

5.9% 29.4% 13.2% 48.5%

6 19 10 35

5.1 20.1 9.8 35.0

60.0% 48.7% 52.6% 51.5%

8.8% 27.9% 14.7% 51.5%

10 39 19 68

10.0 39.0 19.0 68.0

100.0% 100.0% 100.0% 100.0%

14.7% 57.4% 27.9% 100.0%

Count

Expected Count

% within CURB

% of Total

Count

Expected Count

% within CURB

% of Total

Count

Expected Count

% within CURB

% of Total

Laki-laki

Perempuan

Jenis kelamin

Total

rendah sedang tinggi

CURB

Total

Chi-Square Tests

.420a 2 .811

.422 2 .810

.057 1 .812

68

Pearson Chi-Square

Likelihood Ratio

Linear-by-LinearAssociation

N of Valid Cases

Value dfAsymp. Sig.

(2-sided)

1 cells (16.7%) have expected count less than 5. Theminimum expected count is 4.85.

a.

61

PSI * CURB Crosstabulation

Count

CURB

Totalrendah sedang tinggi

PSI rendah 8 5 1 14

sedang 1 24 6 31

tinggi 1 10 12 23

Total 10 39 19 68

Reliability

Scale: ALL VARIABLES

Case Processing Summary

68 100.0

0 .0

68 100.0

Valid

Excludeda

Total

CasesN %

Listwise deletion based on allvariables in the procedure.

a.

Reliability Statistics

.691 2

Cronbach'sAlpha N of Items

62

ANOVA

48.618 67 .726

.000 1 .000 .000 1.000

15.000 67 .224

15.000 68 .221

63.618 135 .471

Between People

Between Items

Residual

Total

Within People

Total

Sum ofSquares df Mean Square F Sig

Grand Mean = 2.13

Intraclass Correlation Coefficient

.528b .333 .680 3.241 67.0 67 .000

.691c .500 .810 3.241 67.0 67 .000

Single Measures

Average Measures

IntraclassCorrelationa Lower Bound Upper Bound

95% Confidence Interval

Value df1 df2 Sig

F Test with True Value 0

Two-way mixed effects model where people effects are random and measures effects are fixed.

Type C intraclass correlation coefficients using a consistency definition-the between-measure variance isexcluded from the denominator variance.

a.

The estimator is the same, whether the interaction effect is present or not.b.

This estimate is computed assuming the interaction effect is absent, because it is not estimable otherwise.c.

63

terapi empirik * Tempat rawat Crosstabulation

Tempat rawat

Totalnon-ICU ICU

terapi empirik ceftriaxone Count 47 3 50

% of Total 69.1% 4.4% 73.5%

ciprofloxacin Count 3 0 3

% of Total 4.4% .0% 4.4%

Levofloxacin Count 0 1 1

% of Total .0% 1.5% 1.5%

Meropenem Count 1 1 2

% of Total 1.5% 1.5% 2.9%

Cefotaxime Count 2 0 2

% of Total 2.9% .0% 2.9%

cefoperazone Count 1 0 1

% of Total 1.5% .0% 1.5%

ceftriaxone+ciprofloxacin Count 5 1 6

% of Total 7.4% 1.5% 8.8%

ceftriaxone+cefotaxime Count 1 0 1

% of Total 1.5% .0% 1.5%

64

ciprofloxacin+clindamycin Count 1 0 1

% of Total 1.5% .0% 1.5%

levofloxacin+meropenem Count 1 0 1

% of Total 1.5% .0% 1.5%

Total Count 62 6 68

% of Total 91.2% 8.8% 100.0%

terapi empirik * CURB Crosstabulation

CURB

Totalrendah sedang tinggi

terapi empirik Ceftriaxone Count 8 28 14 50

% of

Total

11.8% 41.2% 20.6% 73.5%

Ciprofloxacin Count 0 3 0 3

% of

Total

.0% 4.4% .0% 4.4%

Levofloxacin Count 0 1 0 1

% of

Total

.0% 1.5% .0% 1.5%

Meropenem Count 1 1 0 2

% of

Total

1.5% 1.5% .0% 2.9%

65

Cefotaxime Count 0 1 1 2

% of

Total

.0% 1.5% 1.5% 2.9%

cefoperazone Count 0 0 1 1

% of

Total

.0% .0% 1.5% 1.5%

ceftriaxone+ciprofloxacin Count 1 2 3 6

% of

Total

1.5% 2.9% 4.4% 8.8%

ceftriaxone+cefotaxime Count 0 1 0 1

% of

Total

.0% 1.5% .0% 1.5%

ciprofloxacin+clindamycin Count 0 1 0 1

% of

Total

.0% 1.5% .0% 1.5%

levofloxacin+meropenem Count 0 1 0 1

% of

Total

.0% 1.5% .0% 1.5%

Total Count 10 39 19 68

% of

Total

14.7% 57.4% 27.9% 100.0%

66

Lampiran 3. Spreadsheet

NoNomer cm Usia Sex Rawat PSI der.PSI

CURB-65 der.CURB

1 c374377 2 1 2 5 3 4 3

2 C373947 2 1 1 5 3 2 2

3 484757 2 2 1 4 2 2 2

4 c377238 2 1 1 5 3 3 3

5 c383888 2 1 1 2 1 2 2

6 c386336 2 1 1 5 3 5 3

7 c371174 2 2 1 5 3 2 2

8 b371770 2 1 1 4 2 2 2

9 c387630 2 2 1 5 3 2 2

10 c366531 1 2 1 2 1 0 1

11 c377370 1 1 1 3 1 2 2

12 c374186 1 2 1 1 1 0 1

13 c384952 2 1 2 5 3 3 3

14 c430487 2 2 1 5 3 3 3

15 c392798 2 2 2 5 3 4 3

16 b377418 2 2 1 4 2 2 2

17 c398081 2 2 1 4 2 2 2

18 c052585 2 2 1 4 2 2 2

19 b148605 1 1 1 4 2 2 2

20 c268084 1 2 1 3 1 1 1

21 c124793 2 1 1 5 3 2 2

22 c427502 1 2 2 2 1 1 1

23 c428852 2 2 1 5 3 3 3

24 c421710 2 2 1 4 2 3 3

25 c214179 2 1 1 4 2 2 2

26 c400199 2 1 1 4 2 2 2

27 c397469 1 1 1 5 3 2 2

28 c225469 2 1 1 3 1 3 3

29 c397568 1 1 1 4 2 2 2

30 c243988 2 2 1 5 3 2 2

31 c426718 2 2 1 4 2 2 2

32 c273637 2 2 1 4 2 2 2

33 c416097 2 2 1 5 3 2 2

67

Nomer cm Usia Sex Rawat PSI der.psi

CURB-65 der.CURB

34 c417197 2 2 1 4 2 2 2

35 c427437 2 1 1 5 3 3 3

36 c404497 1 2 1 2 1 1 1

37 c428997 2 2 1 5 3 3 3

38 c291567 2 2 1 4 2 2 2

39 c204117 2 1 1 4 2 3 3

40 c422706 2 2 1 4 2 2 2

41 c340066 2 1 1 4 2 2 2

42 c122806 2 1 1 5 3 3 3

43 b274925 2 1 1 3 1 1 1

44 c414835 2 2 1 4 2 3 3

45 c205875 1 2 1 4 2 2 2

46 c424255 1 1 1 4 2 3 3

47 c385434 2 2 1 5 3 3 3

48 c287864 1 1 1 5 3 1 1

49 c393824 1 2 1 3 1 2 2

50 c429414 2 1 1 4 2 2 2

51 c389513 1 1 2 5 3 2 2

52 c396233 1 2 1 4 2 1 1

53 c109693 1 2 1 4 2 2 2

54 c422472 2 1 1 3 1 2 2

55 c343112 2 1 1 4 2 2 2

56 c418952 1 2 1 3 1 2 2

57 b428322 1 1 1 3 1 1 1

58 c413152 2 2 1 4 2 3 3

59 c404311 2 1 1 4 2 2 2

60 b186461 1 2 1 4 2 2 2

61 c415130 1 1 1 5 3 2 2

62 b369240 2 1 1 5 3 2 2

63 c426800 2 1 1 3 1 1 1

64 c364230 1 1 2 4 2 2 2

65 c428429 2 2 1 4 2 3 3

66 c396968 2 2 1 4 2 2 2

67 c384489 2 1 1 4 2 2 2

68 c083541 2 2 1 5 3 3 3

68

NoNomer cm terapi keganasan liver chf serebro ginjal

1 c374377 1 2 2 2 1 12 C373947 7 2 2 1 2 23 484757 1 2 2 1 2 24 c377238 7 2 2 2 1 25 c383888 1 2 2 2 2 26 c386336 7 2 2 2 2 27 c371174 1 2 2 1 2 28 b371770 1 2 2 2 2 19 c387630 7 2 2 1 2 1

10 c366531 1 2 2 2 2 211 c377370 1 2 2 2 2 212 c374186 1 2 2 2 2 213 c384952 7 2 2 2 2 114 c430487 1 2 2 2 1 115 c392798 1 2 1 2 1 216 b377418 2 2 2 2 1 217 c398081 10 2 2 2 1 218 c052585 4 2 2 2 2 219 b148605 1 2 2 2 1 220 c268084 1 2 2 2 2 121 c124793 5 2 2 2 2 222 c427502 4 2 2 2 2 223 c428852 1 2 2 1 2 224 c421710 1 2 2 2 1 225 c214179 1 2 2 2 2 126 c400199 1 2 2 2 2 127 c397469 1 2 2 2 1 228 c225469 1 2 2 2 2 229 c397568 1 2 2 2 2 130 c243988 9 2 2 2 2 231 c426718 2 2 2 1 2 232 c273637 1 2 2 2 2 233 c416097 1 2 1 1 2 234 c417197 1 2 2 1 2 2

69

NoNomer cm Terapi Keganasan Liver Chf Serebro ginjal

35 c427437 1 2 2 1 2 236 c404497 1 2 2 2 2 237 c428997 1 2 2 1 2 138 c291567 1 2 2 2 2 239 c204117 1 2 2 1 2 240 c422706 1 2 2 1 2 241 c340066 1 1 2 2 2 241 c122806 5 2 1 2 2 243 b274925 1 2 2 2 2 244 c414835 1 2 2 2 2 245 c205875 1 1 2 2 2 246 c424255 1 2 2 2 1 247 c385434 1 2 2 2 2 248 c287864 1 2 2 1 2 149 c393824 1 2 2 2 2 250 c429414 1 2 2 2 2 251 c389513 1 1 2 2 2 252 c396233 1 2 2 2 2 253 c109693 1 2 2 1 2 254 c422472 8 2 2 2 2 255 c343112 1 2 2 2 2 256 c418952 2 2 2 2 2 257 b428322 7 2 2 1 2 258 c413152 1 2 2 1 2 259 c404311 1 2 2 2 2 260 b186461 1 2 2 1 2 261 c415130 1 2 2 2 2 262 b369240 1 2 2 1 2 263 c426800 1 2 2 2 2 263 c364230 3 2 2 2 2 265 c428429 6 2 2 2 2 266 c396968 1 2 2 2 2 267 c384489 1 2 2 2 2 268 c083541 1 2 2 1 2 2

70

Lampiran 4. Ethical Clearance

71

Lampiran 5. Surat permohonan peminjaman rekam medik

72

Lampiran 6. Daftar tilik penelusuran rekam medik

NamaUsiaNomer registriJenis kelaminTempat perawatan

Skoring PSIKarakteristik Pasien Poin skor Skor

Faktor Demografi

Usia laki-laki UsiaUsia wanita Usia-10Tinggal di rumah perawatan 10Penyakit Komorbid

Keganasan 30Penyakit liver 20Gagal jantung kongestif 10Penyakit serebrovaskuler 10Penyakit ginjal 10Temuan Pemeriksaan Fisik

Penurunan kesadaran 20Laju pernapasan ≥ 30 x per menit 20Tekanan darah sistolik <90 mmHg 20Suhu < 35 oC / ≥40 oC 15Nadi ≥ 125 x per menit 10Temuan Laboratorium

pH <7,35 30BUN>11mmol/L atau ≥30mg/dL 20Natrium <130mmol/L 20Gula darah >14 mmol/L atau ≥250mg/dL

10

Hematokrit <30% 10p02 <60mmHg 10Efusi pleura 10Total skor PSIDerajat keparahan

73

Skoring CURB-65Karakteristik Poin Skor Skor

Penurunan kesadaran 1Urea nitrogen darah > 20 mg per dL (7.14 mmol per L)

1

Laju pernapasan ≥ 30 x per menit 1Tekanan darah (sistolik < 90 mm Hg atau diastolik ≤ 60 mm Hg)

1

Usia ≥ 65 tahun 1Total skor CURB-65Derajat keparahan

Terapi empirik

74

Lampiran 7. Dokumentasi penelitian

75

Lampiran 8. Biodata Mahasiswa

Identitas

Nama : Nina Widasari

NIM : 22010110120119

Tempat / tanggal lahir : Takengon, 3 Juli 1992

Jenis Kelamin : Perempuan

Alamat : Jl. Azalea IV no. 8U Kompleks Cemara Asri

Medan

Nomor HP : 083838808789

E-mail : ninawidasariyanis@gmail.com

Riwayat Pendidikan Formal

1. SD : 1998 Lulus tahun : 2004

2. SMP : 2004 Lulus tahun : 2007

3. SMA : 2007 Lulus tahun : 2010

4. FK UNDIP : Masuk tahun 2010

Keanggotan Organisasi

1. BEM SENIOR FK Undip tahun 2010